Evidence map›Paper›PMID 41010375›Full record

ArticleLife (Basel, Switzerland)2025

Biomarkers for Early Detection of Cisplatin-Induced Nephrotoxicity.

Nikolay Dimov, Antoniya Yaneva, Evelina Valcheva, Gabriela Raycheva, Veselin Popov, Raya Delipavlova, Dimitar Nikolov, Zhanet Grudeva-Popova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nikolay DimovNephrology Section, Second Department of Internal Diseases, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.ORCID 0000-0002-0822-9454
Antoniya YanevaDepartment of Medical Informatics, Biostatistics and E-learning, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.ORCID 0000-0002-8778-2660
Evelina ValchevaClinic of Nephrology, University Multiprofile Hospital for Active Treatment "Sv. Georgi"-Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.ORCID 0009-0000-8755-349X
Gabriela RaychevaDepartment of Clinical Oncology, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Veselin PopovDepartment of Clinical Oncology, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.ORCID 0000-0002-6423-9665
Raya DelipavlovaDepartment of Clinical Laboratory, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Dimitar NikolovNephrology Section, Second Department of Internal Diseases, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Zhanet Grudeva-PopovaDepartment of Clinical Oncology, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.

Funding

Medical University Plovdiv internal university scientific project № HO-20/2023
6 · The paper itself

Abstract

Nephrotoxicity is a common complication during antineoplastic therapy, particularly when platinum-based medications are used. Early detection of this condition is crucial for improving risk stratification and management, thereby enhancing decision-making in kidney disease treatment. However, traditional biomarkers for renal assessment lack sensitivity in identifying early or subclinical damage, underscoring the need for novel and more precise markers. This study aimed to investigate the effectiveness of urinary KIM-1, clusterin, nephrin, and serum cystatin C in detecting nephrotoxicity associated with platinum-based therapies. A total of 43 patients with different oncological diseases participated in the prospective study, divided into two groups based on the nephrotoxic potential of the administered drugs: patients treated with cisplatin (high-risk group for nephrotoxicity) and patients treated with oxaliplatin/carboplatin (low-to-moderate risk group for nephrotoxicity). The results showed that nephrotoxicity, determined as a decrease in eGFR of >10 mL/min/1.73 m

Indexed as

cystatin CeGFR declinenephrotoxicityplatinum-based therapyuClusterinuKIM-1uNephrin

Identifiers

PMID41010375
PMCPMC12471489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.